Antidepressant Drugs

Producción científica: Chapter

Resumen

This article covers the drugs used to treat Major Depressive Disorder (MDD). Clinical information about MDD and one of its consequences, suicide, is presented initially. An extensive assessment of the various classes of antidepressant drugs, traditional ones such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), and their successors such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are presented. Comparative information is provided also for other types of antidepressants as well as for two newly approved drugs, brexanolone for postpartum depression and esketamine for treatment resistant depression. Information is covered about their efficacy and adverse effects. The last portion of the article describes the mechanisms of action by which conventional and novel antidepressants promote changes that ultimately account for improvement of depressive symptomatology. Within this section, the reader will learn about acute as well as long-term changes caused by antidepressants in different neurons, receptors, intracellular signaling proteins, and genes. This section also briefly describes some current research on potential novel antidepressants. The entire article has tables and figures to assist the reader.

Idioma originalEnglish (US)
Título de la publicación alojadaComprehensive Pharmacology
EditorialElsevier
Páginas308-324
Número de páginas17
Volumen3
ISBN (versión digital)9780128204726
DOI
EstadoPublished - ene 1 2022

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics
  • General Medicine

Huella

Profundice en los temas de investigación de 'Antidepressant Drugs'. En conjunto forman una huella única.

Citar esto